Allarity Therapeutics, Inc. (NASDAQ:ALLR – Free Report) – Equities research analysts at Ascendiant Capital Markets upped their Q3 2026 EPS estimates for shares of Allarity Therapeutics in a research report issued on Tuesday, September 15th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings of ($0.21) per share for the quarter, up from their prior estimate of ($0.25). Ascendiant Capital Markets has a “Buy” rating and a $10.25 price objective on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($0.92) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.21) EPS and FY2027 earnings at ($0.86) EPS.
Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04.
Read Our Latest Stock Analysis on Allarity Therapeutics
Allarity Therapeutics Price Performance
Allarity Therapeutics stock opened at $1.09 on Friday. Allarity Therapeutics has a 1 year low of $0.77 and a 1 year high of $1.84. The stock has a market cap of $17.34 million, a price-to-earnings ratio of -1.40 and a beta of 0.56. The firm has a 50-day moving average of $1.29 and a two-hundred day moving average of $1.33.
Allarity Therapeutics Company Profile
Allarity Therapeutics, Inc is a clinical-stage biotechnology company focused on developing personalized cancer treatments. The company uses its Drug Response Predictor (DRP) technology to analyze tumor biology and identify patients who may be more likely to respond to specific therapies.
Allarity’s development programs have included dovitinib, an oral multikinase inhibitor investigated for use in advanced cancers, as well as other oncology candidates and drug-specific DRP companion diagnostics.
Read More
- Five stocks we like better than Allarity Therapeutics
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
